---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-121437"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:15:49.623240+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Syndax Q3 net loss $84.1M; revumenib PDUFA Dec 26; Niktimvo approved; $350M royalty funding

## Summary
- Net loss $84.1M ($0.98/share) vs $51.1M ($0.73) in Q3 2023; R&D $71.0M, SG&A $31.1M.
- Revumenib NDA under FDA RTOR with PDUFA Dec 26, 2024; topline mNPM1 AML data expected Q4 2024, potential sNDA 1H25.
- Niktimvo (axatilimab) approved by FDA for chronic GVHD after ≥2 prior lines; launch early Q1 2025.
- $350M royalty funding agreement with Royalty Pharma (13.8% royalty on U.S. Niktimvo sales) expected to fund to profitability.
- Full-year 2024 guidance: R&D $245-250M, total op. exp. $365-370M; cash $399.6M as of Sep 30.

## SEC filing metadata
- accession: 0000950170-24-121437
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000095017024121437/0000950170-24-121437-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000095017024121437/sndx-20241105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-121437
- JSON: https://secwatch.observer/filing/0000950170-24-121437.json
- Plain text: https://secwatch.observer/filing/0000950170-24-121437.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.